TandemAI is redefining the future of drug discovery. As a leading AI-native biotechnology company, we've built a commercially validated platform that's transforming how the world's medicines get made — spanning small molecules, peptides, and antibody-peptide conjugates (APCs).
At our core is a breakthrough dual-engine system: a proprietary world model paired with self-evolving AI scientist agents that never sleep. Together, they power a fully autonomous, closed-loop discovery cycle, where computation guides the wet lab, and every experiment feeds back to sharpen the model. The result is an intelligent, end-to-end drug discovery engine that takes programs from target validation all the way to Preclinical Candidate Compound (PCC), dramatically accelerating both speed and success in the hunt for best-in-class therapeutics.
TandemAI currently powers 200+ partnerships with pharmaceutical companies and research institutions worldwide, including four of the global top 10 and multiple top-20 multinational pharma leaders. Our pipeline spans 50+ collaborative and proprietary programs, with several already advancing through clinical development.
Fueling this momentum is backing from tier-1 global investors — OrbiMed, Qiming Venture Partners, Sequoia Capital, and Chengwei Capital. TandemAI has been spotlighted in the Nature Index Global AI Drug Discovery Innovation Map, named to the Forbes Asia 100 to Watch list, and forged strategic R&D alliances with world-class AI institutions including Mila — Quebec Artificial Intelligence Institute.
